Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer

  Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer

Brings wealth of clinical research and regulatory submission expertise to help
                               advance pipeline

Business Wire

NEW YORK -- April 25, 2013

Retrophin, Inc. (OTCQB: RTRX), a pharmaceutical company focused on the
discovery and development of drugs for the treatment of debilitating and often
life-threatening diseases for which there are currently no viable patient
options, today announced that it has named Horacio Plotkin, M.D. as Chief
Medical Officer, effective May 13. He will be based in Cambridge, MA, where
Retrophin plans to open an office for its clinical, medical, and regulatory
operations.

Most recently, Dr. Plotkin served as Executive Medical Director of Clinical
Research for Alexion Pharmaceuticals. There, he was the Global Medical Lead
for an investigational treatment for hypophosphatasia, a rare metabolic bone
disease. Previously, he was Senior Medical Director of Clinical Research at
Enobia Pharma and Medical Director of Clinical Research at Genzyme
Corporation. At Genzyme, he led his team to the approval of a treatment for
Pompe disease. Earlier in his career, he held various positions at the
Children’s Hospital & Medical Center in Omaha, NE.

“Dr. Plotkin’s depth of clinical research experience will be invaluable as we
continue to advance our pipeline,” said Martin Shkreli, Founder, President and
Chief Executive Officer of Retrophin. “His track record of developing
life-changing pharmaceutical products, coupled with his passionate dedication
to patients suffering from debilitating diseases, make him a great asset to
Retrophin. We’re thrilled to have Dr. Plotkin join our team.”

“Retrophin’s focus on catastrophic diseases, specifically those that affect
children, is an ideal fit for my professional background and interests,” said
Dr. Plotkin. “I’m eager to contribute to Retrophin’s bright future and make a
difference in patients’ lives.”

Dr. Plotkin earned his M.D. from the University of Buenos Aires School of
Medicine. He currently serves as Adjunct Associate Professor of Pediatrics and
Orthopedic Surgery at the University of Nebraska Medical Center.

About Retrophin

Retrophin is a pharmaceutical company focused on the discovery and development
of drugs for the treatment of debilitating and often life-threatening diseases
for which there are currently no viable patient options. The Company is
currently focused on several catastrophic diseases affecting children,
including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate
Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and
others. Retrophin’s lead compound, RE-021, is scheduled to begin enrollment in
a potentially pivotal Phase 2 clinical trial for FSGS during the first half of
2013.

Forward-Looking Statements

This press release contains “forward-looking statements” as that term is
defined in the Private Securities Litigation Reform Act of 1995, regarding the
research, development and commercialization of pharmaceutical products. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay, divert
or change any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement can be
guaranteed. Forward-looking statements in the press release should be
evaluated together with the many uncertainties that affect the Company’s
business. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events, or otherwise.

Contact:

Retrophin, Inc.
Martin Shkreli, CEO
212-983-1310
martin.shkreli@retrophin.com
or
Rx Communications Group
Paula Schwartz (Investors)
917-322-2216
pschwartz@rxir.com
or
6 Degrees
Annie Starr (Media)
973-415-8838
astarr@6degreespr.com